India’s second-largest drugmaker Cipla Ltd on Wednesday announced that it has signed a licensing agreement with a Belgium-based firm, Multi G for the distribution of their coronavirus Rapid Antibody test kit, across most emerging markets and Europe. As part of this agreement, Cipla will be responsible for distribution of the Covid-19 rapid antibody kit that will be manufactured by MultiG. Sensitivity and specificity exceeds 92%Marketed under the brand name ‘Covi-G’, this was among the earliest Antibody kits to declare CE-compliance and is awaiting approval by ICH country regulators. It tests for both IgM and IgG antibodies, using a single-prick blood test using of the test result indicator visual interpretation. The kit gives results within 10 minutes.

Source: Mint November 18, 2020 03:28 UTC